Clinical characterization and risk profile of individuals seeking genetic counseling for hereditary breast cancer in Brazil

Journal of Genetic Counseling

Volumn 16, Issue 3, 2007, Pages 363-371

  Palmero, Edenir Inez ^a,b   Ashton Prolla, Patricia ^a,b   Da Rocha, José Cláudio C ^c   Vargas, Fernando Regla ^d,e   Kalakun, Luciane ^b   Blom, Melissa Brauner ^b   Azevedo, Sérgio J ^a,b   Caleffi, Maira ^f,g   Giugliani, Roberto ^a,b   Schüler Faccini, Lavinia ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c A C CAMARGO CANCER CENTER   (Brazil)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^e FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^f HOSPITAL MOINHOS DE VENTO   (Brazil)

^g HOSPITAL SANTA RITA   (Brazil)

Author keywords

Cancer genetic counseling; Hereditary breast cancer; Lifetime risk of cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BRAZIL; BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SCREENING; CLINICAL EVALUATION; CLINICAL GENETICS; DEMOGRAPHY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HEALTH CARE ACCESS; HEALTH SERVICE; HELP SEEKING BEHAVIOR; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MODEL; ONCOGENE; PROBABILITY; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; BRAZIL; BRCA2 PROTEIN; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC COUNSELING; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMANS; MIDDLE AGED; NEOPLASTIC SYNDROMES, HEREDITARY; OVARIAN NEOPLASMS; PROBABILITY; RISK; RISK ASSESSMENT; SOCIOECONOMIC FACTORS; UBIQUITIN-PROTEIN LIGASES;

EID: 34249947751     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-006-9073-0     Document Type: Article

References (32)

1. Achatz, M. I. W., & Hainaut, P. (2005). TP53 gene and Li-Fraumeni syndrome. Appl Cancer Res, 25, 51-57.
2. ASCO Subcommittee on Genetic Testing for Cancer Susceptibility (1996). Statement of the American Society of Clinical Oncology: Genetic Testing for Cancer Susceptibility. J Clin Oncol, 14, 1730-1736.
3. Birch, J. M., Hartley, A. L., Tricker, K. J., Prosser, J., Condie, A., Kelsey, A. M., et al. (1994). Prevalence and diversity of constitutional mutations in the p53 gene among Li-Fraumeni families. Cancer Res, 54, 1298-1304.
4. Borras, J. M., Guillen, M., Sanchez, V., Junca, S., & Vicente, R. (1999). Educational level, voluntary private health insurance and opportunistic cancer screening among women in Catalonia (Spain). Eur J Cancer Prev, 8, 427-434.
5. Claus, E. B., Risch, N., & Thompson, D. (1994). Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer, 73, 643-651.
6. Easton, D. F. (1999). How many more breast cancer predisposition genes are there? Br Cancer Res, 1(1), 14-17.
7. Eisen, A., Rebbeck, T. R., Wood, W. C., & Weber, B. L. (2000). Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol, 18, 1980-1995.
8. Eng C. (1997). Cowden syndrome. J Genet Counsel, 6, 181.
9. Epplein, M, Koon, K. P., Ramsey, S. D., & Potter, J. D. (2005). Genetic services for familial cancer patients: a follow-up survey of National Cancer Institute Cancer Centers. J Clin Oncol, 23(21), 4713-4718.
10. Evans, D. G. R., Burnell, L. D., Hopwood, P., & Howell, A. (1993). Perception of risk in women with a family history of breast cancer. Br J Cancer, 67, 612-614.
11. Frank, T. S., Manley, S. A., Olopade, O. I., Cummings, S., Garber, J. E., Bernhardt, B., et al. (1998). Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol, 16, 2417-2425.
12. Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., et al. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst, 81, 1879-1886.
13. Gorin, S. S., & Heck, J. E. (2005). Cancer screening among Latino subgroups in the United States. Prev Med, 40, 515-526.
14. Hopwood, P. (2000). Breast cancer risk perception: what do we know and understand? Br Cancer Res, 2, 387-391.
15. Huiart, L., Eisinger, F., Stoppa-Lyonnet, D., Lasset, C., Noguès, C., Vennin, P., et al. (2002). Effects of genetic consultation on perception of a family risk of breast/ovarian cancer and determinants of inaccurate perception after the consultation. J Clin Epidemiol, 55, 665-675.
16. Julian-Reynier, C., Eisinger, F., Chabal, F., Aurran, Y., Nogues, C., Vennin, P., et al. (1996). Cancer genetics clinics: target population and consultees'expectations. Eur J Cancer, 32A(3), 391-403.
17. Julian-Reynier, C., Eisinger, F., Chabal, F., Aurran, Y., Bignon, Y. J., Nogues, C., et al. (1998). Cancer genetics clinics: why do women who already have cancer attend? Eur J Cancer, 34(10), 1549-1553.
18. Lerman, C., Rimer, B. K., Daly, M., Lustbader, E., Sands, C., Blashem, A., et al. (1994). Recruiting high risk women into a breast cancer health promotion trial. Cancer Epidemiol Biomarkers Prev, 3, 271-276.
19. Leventhal, H., Kelly, K., & Leventhal, E. A. (1999). Population risk, actual risk, perceived risk, and cancer control: a discussion. J Natl Cancer Inst Monographs, 25, 81-85.
20. Li, F. P., & Fraumeni, J. F. Jr. (1969). Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med, 71, 747-752.
21. Llerena, J. C. Jr. (2002). Medical Genetics, Single Brazilian Health System (SUS) and integrated aspect in health attention and care. Ciência & Saúde Coletiva, 7, 17-41.
22. Meijers-Heijboer, H., Wijnen, J., Vasen, H., Wasielewski, M., Wagner, A., Hollestelle, A., et al. (2003). The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet, 72, 1308-1314.
23. Miki, Y., Swenson, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266, 66-71.
24. Offit, K. (1998). The common hereditary cancers. In: Clinical cancer genetics: Risk counseling and management (pp. 66-156). New York: Wiley-Liss.
25. Penchaszadeh, V. B. (2000). Community genetics in Latin America: challenges and perspectives. Community Genet, 3, 124-127.
26. Penchaszadeh, V. B., Christianson, A. L., Giugliani, R., Boulyjenkov, V., & Katz, M. (1999). Services for the prevention and management of genetic disorders and birth defects in developing countries. Community Genet, 2, 196-201.
27. Ritvo, P., Irvine, J., Robinson, G., Brown, L., Murphy, K. J., Matthew, A., et al. (2002). Psychological adjustment to familial-genetic risk assessment for ovarian cancer: predictors of nonadherence to surveillance recommendations. Gynecol Oncol, 84, 72-80.
28. Sobol, H., Bignon, Y. J., Bonaiti, C., Cuisinger, J., Lasset, C., Lortholary, A., et al. (1999). Four years analysis of cancer genetics clinics activities in France from 1994 to 1997: a survey on 801 patients. French Cooperative Network/Groupe Genetique et Cancer de la Federation Nationale des Centres de Lutte Contre le Cancer. Dis Markers, 15(1-3), 15-29.
29. Thorson, A. G., Knezetic, J. A., & Lynch, H. T. (1999). A century of progress in hereditary nonpolyposis colorectal cancer (Lynch syndrome). Dis Colon Rectum, 42(1), 1-9.
30. U.S. Preventive Services Taskforce (2005). Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med, 143(5), 355-361.
31. Wonderling, D., Hopwood, P., Cull, A., Douglas, F., Watson, M., Burn, J., et al. (2001). A descriptive study of UK cancer genetics services: an emerging clinical response to the new genetics. Br J Cancer, 85(2), 166-170.
32. Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., et al. (1994). Localization of a breast cancer susceptibility gene, BRCA2 to chromosome 13q12-13. Science, 265, 2088-2090.